June 1, 2024Annals of the Rheumatic Diseases

Pos0046 Preliminary Results of an Open-Label, Multicentre, Phase 1/2 Study to Assess Safety, Efficacy and Cellular Kinetics of Ytb323 (Rapcabtagene Autoleucel), a Rapidly Manufactured Car T-Cell Therapy Targeting Cd19 on B Cells, for Severe Refractory Systemic Lupus Erythematosus

View Full Paper

Ask AI

Bookmark

Authors

JCJ. Cortés-HernándezUniversitat Autònoma de Barcelona PBPere BarbaHebron University JÁJ.M. Álvaro-GraciaUniversidad Complutense de Madrid

Discussion

Member takes

Implication

Randomized trial reports initial safety and disease activity reduction in severe refractory systemic lupus erythematosus, suggesting therapeutic viability of rapcabtagene autoleucel.

Key Points

Deep depletion of B cells and substantial disease activity reductions occurred following rapcabtagene autoleucel infusion in patients with severe refractory systemic lupus erythematosus.
Cytokine release syndrome occurred in four of six treated individuals at mild grades, resolving with tocilizumab intervention alongside manageable transient cytopenias.
Open-label, single-arm, multicentre phase 1/2 study evaluation demonstrates robust CAR T-cell therapy expansion, supporting continued clinical investigation in autoimmune disease.

Cite This Study

Cortés-Hernández et al. (2024) studied this question.

synapsesocial.com/papers/68e669beb6db6435875f5de7 https://doi.org/10.1136/annrheumdis-2024-eular.1768

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial reports initial safety and disease activity reduction in severe refractory systemic lupus erythematosus, suggesting therapeutic viability of rapcabtagene autoleucel.

Pos0046 Preliminary Results of an Open-Label, Multicentre, Phase 1/2 Study to Assess Safety, Efficacy and Cellular Kinetics of Ytb323 (Rapcabtagene Autoleucel), a Rapidly Manufactured Car T-Cell Therapy Targeting Cd19 on B Cells, for Severe Refractory Systemic Lupus Erythematosus

Discussion

Member takes

Implication

Key Points

Cite This Study

Pos0046 Preliminary Results of an Open-Label, Multicentre, Phase 1/2 Study to Assess Safety, Efficacy and Cellular Kinetics of Ytb323 (Rapcabtagene Autoleucel), a Rapidly Manufactured Car T-Cell Therapy Targeting Cd19 on B Cells, for Severe Refractory Systemic Lupus Erythematosus

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider